For the quarter ending 2026-03-31, EKSO made $2,141K in revenue. -$6,675K in net income. Net profit margin of -311.77%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 2,141 | 3,140 | 4,227 | 2,057 |
| Cost of revenue | 1,067 | 1,469 | 1,678 | 1,238 |
| Gross profit | 1,074 | 1,671 | 2,549 | 819 |
| Sales and marketing | 2,051 | 2,444 | 1,313 | 1,690 |
| Research and development | 583 | 641 | 550 | 852 |
| General and administrative | 4,058 | 3,095 | 2,088 | 2,252 |
| Total operating expenses | 6,692 | 6,180 | 3,951 | 4,794 |
| Loss from operations | -5,618 | -4,509 | -1,402 | -3,975 |
| Interest expense, net | 143 | 154 | 18 | 65 |
| (loss) gain on revaluation of warrant liabilities | -727 | 0 | 0 | 0 |
| Loss on modification of warrant | - | 0 | 0 | 0 |
| Finance cost associated with warrant issuance | 145 | - | - | - |
| Unrealized (gain) loss on foreign exchange | -239 | -4 | 4 | 1,339 |
| Other expense, net | -13 | -7 | -5 | -8 |
| Total other (expense) income, net | -1,267 | -165 | -19 | 1,266 |
| Net loss | -6,885 | -4,674 | -1,421 | -2,709 |
| Foreign currency translation adjustments | - | 8 | - | - |
| Other comprehensive income (loss) | 210 | - | -17 | -1,107 |
| Comprehensive loss | -6,675 | -4,666 | -1,438 | -3,816 |
| Basic EPS | -2.04 | -1.923 | -0.54 | -1.24 |
| Diluted EPS | -2.04 | -1.228* | -0.54 | -1.24 |
| Basic Average Shares | 3,563,000 | 2,426,000* | 2,616,000 | 2,180,000 |
EKSO BIONICS HOLDINGS, INC. (EKSO)
EKSO BIONICS HOLDINGS, INC. (EKSO)